Shares of HemaCare Co. (OTCMKTS:HEMA – Get Free Report) were up 0.6% during trading on Thursday . The company traded as high as $25.31 and last traded at $25.31. Approximately 5,400 shares traded hands during trading, a decline of 86% from the average daily volume of 39,950 shares. The stock had previously closed at $25.16.
HemaCare Stock Performance
The business’s 50 day simple moving average is $25.31 and its 200 day simple moving average is $25.31.
About HemaCare
HemaCare Corporation is a specialty life sciences company that supplies primary human blood and bone marrow-derived cells for research, drug development and medical device evaluation. The company’s product portfolio includes peripheral blood mononuclear cells (PBMCs), buffy coats, hematopoietic stem and progenitor cells, whole blood, bone marrow aspirates and custom-processed cell fractions. These offerings are designed to support preclinical studies, translational research and in vitro assays across immunology, hematology, oncology and regenerative medicine applications.
In addition to off-the-shelf cell products, HemaCare provides custom cell isolation services, donor screening and logistics solutions tailored to the needs of pharmaceutical, biotechnology and academic customers.
Read More
- Five stocks we like better than HemaCare
- 3 Stocks Rallying on Micron’s Price Boost: Substance or Hype?
- Snowflake and the Snowballing Impact of its AI Flywheel
- AI’s Biggest Bottleneck Could Make These 2 Stocks Soar
- These 3 Beaten-Down Stocks Just Saw $25 Million in Insider Buying
Receive News & Ratings for HemaCare Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for HemaCare and related companies with MarketBeat.com's FREE daily email newsletter.
